What will the average number of measles cases be during Trump's term?
I assess a 72% independent probability that the average annual number of US measles cases across 2025–2028 will meet or exceed ~3,000 per year (i.e., the 'Yes' outcome). This reflects the strong acceleration in 2026, weak policy response, and high-risk pockets that make a sustained multi-year elevated average more likely than not.
Analysis
**Stage 1 — Blind analysis (ignore market prices):**
Since 2000 the U.S. has effectively maintained elimination-level measles activity; that changed decisively in 2025–mid‑2026. Confirmed totals of 2,184 in 2025 and ~2,170 by mid‑2026 (with projections of ~4,300–4,500 for full‑year 2026) mean the first two years of the Trump administration already average roughly 3,200–3,300 cases/year. That two‑year baseline dominates any four‑year average unless 2027–2028 see substantial suppression.
I built a scenario distribution around reasonable trajectories for 2027–2028: - "Sustained high" (25–40% weight): continued transmission at 2026 levels or higher (annual 3,500–5,000), driven by large under‑immunized clusters, ongoing spread in congregate settings (detention centers, schools, religious communities), and limited federal intervention. This produces a 4‑year average comfortably above 3,000. - "Moderate decline" (30–40% weight): partial control via local campaigns, natural depletion of susceptible clusters, or state-level interventions produce 2027–28 totals of ~1,500–3,000 per year; the 4‑year average may sit near or slightly below 3,000 depending on the realized numbers. - "Rapid control" (20–30% weight): aggressive vaccination drives, improved outbreak response, and favorable stochastic fadeouts reduce 2027–28 to under ~1,000/year; this pulls the 4‑year average well below 3,000.
Combining those scenario weights and the hard evidence of acceleration in early 2026 (rate roughly doubling vs. 2025), I estimate the probability that the 2025–2028 average will be ≥3,000/year at approximately 72%. Key quantitative anchors: 2025 = 2,184; 2026 proj ≈4,400 (midpoint of 4,300–4,500). If 2027–28 average even modestly above ~2,400 each, the four‑year mean remains ≥3,000. Given the epidemiological drivers and policy context, those modestly elevated 2027–28 values are more likely than a rapid return to elimination levels.
**Stage 2 — Market calibration (incorporate current market price Yes: 0.28):**
The market is pricing the 'Yes' outcome at ~28%, substantially lower than my 72% independent estimate. Possible reasons markets are underpricing 'Yes': - Traders are extrapolating optimism about a strong public health response or assuming rapid natural burn‑out, underweighting the observed acceleration and the size of under‑immunized pockets. - Market participants may be confusing reported mid‑year counts with full‑year trends or expecting dramatic mid‑course policy corrections that have not materialized. - Liquidity and information asymmetry: despite large volume, some traders may be risk‑averse or influenced by headlines claiming the outbreak is peaking; others may be hedging against long‑odds policy shifts. - The question/threshold used by the market could differ from my explicit threshold (≥3,000); if market's 'Yes' corresponds to a materially higher threshold, that would explain the lower price.
Why the market could be correct (factors that would lower my estimate): - A coordinated, high‑impact vaccination push across high‑risk states or federal action could materially curtail transmission in 2027–28. - Rapid natural herd immunity in the most interconnected susceptible clusters could cause a sharper-than-expected decline. - Reporting artifacts or changing case definitions could change apparent totals.
Net calibration: given the real‑world evidence of an accelerating outbreak, large, concentrated susceptible populations, and the administration's documented policy choices that slow federal-level mitigation, I view the market's 28% as a meaningful underpricing of sustained elevated average risk. Traders seeking an edge should favor the 'Yes' side, while remaining cognizant of tail risks that could drive rapid declines.
Arguments
For
- Confirmed acceleration in 2026 — roughly 2,170 cases in the first half of 2026 with a projected full year ~4,300–4,500 — strongly biases the four‑year mean upward.
- Large, high‑attack outbreaks (e.g., 610 cases in Spartanburg) show measles spreads efficiently in under‑immunized pockets, indicating sustained potential for large annual counts.
- Policy environment: documented cancellations/postponements of CDC assessments/ACIP meetings and criticized federal decisions reduce the likelihood of rapid nationwide suppression.
- Transmission in congregate settings (detention centers, schools) creates reservoirs that can seed repeated outbreaks across years.
Against
- Public health interventions (state or federal) could be scaled up rapidly in response to the record 2026 numbers, materially lowering 2027–28 incidence.
- Measles epidemics often display burnout: once highly connected susceptible clusters are infected, transmission can decline sharply absent new susceptible influxes.
- Seasonality and stochastic fadeouts could reduce 2027 totals, especially if large outbreaks are concentrated and not widely dispersed.
- Behavioral response: increased public awareness and voluntary vaccination increases following large outbreaks could reduce future spread more than current policy suggests.
Key drivers
- 2026 acceleration: first half 2026 counts imply a full‑year figure (~4,300–4,500) that dramatically raises the term average.
- Vaccination coverage in concentrated pockets (religious, geographic, detention centers): these determine local outbreak size and persistence.
- Federal and state policy responses: speed and scale of vaccination campaigns, school mandates, and targeted outreach.
- Population immunity dynamics: depletion in susceptible subpopulations vs. replenishment through births and importations.
Risk factors
- Rapid, well‑executed catch‑up vaccination campaigns and emergency public health measures could sharply reduce cases in 2027–28.
- Natural epidemic burnout in highly connected susceptible clusters can produce abrupt declines in incidence.
- Changes in surveillance, testing, or case definitions that alter reported counts (upward or downward).
- High variance (stochasticity): measles outbreaks can be highly path‑dependent — a single super‑spreading event or an early fade‑out materially changes the four‑year average.
Scenarios
Best case
Aggressive, coordinated vaccination campaigns across states and targeted outreach to under‑immunized groups in late 2026 and 2027 drive 2027–2028 annual cases down to low hundreds (<1,000/year). With 2025=2,184 and 2026~4,400, the four‑year average falls below 2,000 and the 'Yes' threshold (≥3,000) fails — this yields a low probability path but a sharp public health win.
Most likely
Partial control: 2027–2028 see reduced but still elevated transmission (annual totals 2,000–3,500). The 4‑year average clusters around 3,000–3,500/year — above the ~3,000 threshold — producing a Yes outcome. This reflects some local improvements and natural dynamics but no sweeping reversal of the 2026 acceleration.
Worst case
Measles becomes entrenched in multiple high‑population pockets and spreads more widely with repeated large outbreaks in 2027–2028 (annual totals 4,000–6,000+). Combined with 2025–2026, the four‑year average rises above 4,000/year. This scenario is driven by weak policy response, continued vaccine refusal, and international importations.
More from this day
- pop culturePolymarketEnded
What will happen before GTA VI?
AI9%MKT51%Edge-42HypedI think the chance of another pandemic before GTA VI is materially below the current market price. The most likely outcome is that today’s outbreaks remain serious but contained, with no event reaching true pandemic status before November 19, 2026.
- EconomicsKalshi2y
Will there be a Trump economic boom?
AI8%MKT50%Edge-42HypedIndependent assessment: very unlikely — I assign an 8% chance that any U.S. quarterly real GDP (annualized) will exceed 5% in Q1 2025–Q4 2028. The data and policy environment point strongly against a sustained or one‑off 5%+ quarter, though low‑probability shocks could still produce a spike.
- techPolymarketEnded
Which company has the best Math AI model end of July?
AI54%MKT13%Edge+41Hidden GemGoogle is the current leader on the relevant Arena math leaderboard, but the margin is thin and several major competitors are close enough to overtake it before month-end. I give Google a modest edge over a coin flip, slightly above the market price, because it starts from first place and still has room for a late July Gemini update.